14 August 2020 - Parsortix update
The company has revealed that testing by the Laboratory of Translational Oncology at the University of Crete has proved the benefits of ANGLE's Parsortix system in testing whether cancer patients would benefit from the use of immunotherapy drugs. Whilst current biopsy testing fails to provide a reliable result, the Parsortix system provides a more positive result. Although the findings should be viewed as preliminary, the results are clearly very promising due to the very high cost of immunotherapy drugs (£150,000 per patient) as identifying which patients will benefit from them is clearly key . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.